Interleukin 2

Interleukin 2 (IL-2) is a type of cytokine signaling molecule in the immune system. It plays a crucial role in the body's natural defense against infection and disease. IL-2 is a protein that is produced by activated T cells, a type of white blood cell, and is essential for the growth, proliferation, and differentiation of T cells.

Structure and Function[edit]

IL-2 is a glycoprotein with a molecular weight of approximately 15.5 kDa. It is encoded by the IL2 gene located on chromosome 4 in humans. The primary function of IL-2 is to stimulate the growth and differentiation of T cells, particularly CD4+ T cells and CD8+ T cells.

IL-2 binds to the IL-2 receptor (IL-2R), which is expressed on the surface of T cells. The IL-2 receptor is composed of three subunits: alpha (CD25), beta (CD122), and gamma (CD132). The binding of IL-2 to its receptor triggers a cascade of intracellular signaling pathways that lead to T cell proliferation and survival.

Role in the Immune System[edit]

IL-2 is critical for the immune response. It promotes the development of regulatory T cells (Tregs), which are essential for maintaining immune tolerance and preventing autoimmune diseases. IL-2 also enhances the cytotoxic activity of natural killer cells and supports the differentiation of B cells into antibody-producing plasma cells.

Clinical Applications[edit]

IL-2 has been used in clinical settings as a therapeutic agent. It is approved for the treatment of certain types of cancer, such as renal cell carcinoma and metastatic melanoma. High-dose IL-2 therapy can stimulate the immune system to attack cancer cells, although it is associated with significant side effects.

In addition to cancer therapy, IL-2 is being investigated for its potential use in treating autoimmune diseases and in immunotherapy for infectious diseases.

Research and Development[edit]

Ongoing research is focused on understanding the precise mechanisms of IL-2 signaling and its role in immune regulation. Scientists are also exploring ways to modify IL-2 to enhance its therapeutic efficacy while minimizing adverse effects.

History[edit]

IL-2 was first discovered in the 1970s as a factor that could stimulate the growth of T cells in vitro. The cloning of the IL2 gene in the early 1980s paved the way for the development of recombinant IL-2 for clinical use.

Also see[edit]